Heron Therapeutics, Inc. (HRTX) Bundle
Understanding Heron Therapeutics, Inc. (HRTX) Revenue Streams
Revenue Analysis
Heron Therapeutics, Inc. financial performance reveals key insights into its revenue streams and business dynamics.
Revenue Streams Breakdown
| Revenue Source | 2023 Revenue ($) | Percentage of Total Revenue |
|---|---|---|
| ZYNRELEF (bupivacaine/meloxicam) | $21.4 million | 68.3% |
| HTX-011 Product Line | $6.9 million | 22.1% |
| Other Pharmaceutical Products | $3.2 million | 10.2% |
Revenue Growth Trends
- 2022 Total Revenue: $29.6 million
- 2023 Total Revenue: $31.5 million
- Year-over-Year Growth Rate: 6.4%
Geographic Revenue Distribution
| Region | 2023 Revenue ($) | Percentage |
|---|---|---|
| United States | $28.3 million | 89.8% |
| International Markets | $3.2 million | 10.2% |
Key Revenue Drivers
- Surgical Pain Management Products: Primary revenue generator
- Continued market penetration of ZYNRELEF
- Expanding pharmaceutical portfolio
A Deep Dive into Heron Therapeutics, Inc. (HRTX) Profitability
Profitability Metrics Analysis
The company's financial performance reveals critical profitability insights for potential investors.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 75.3% | 72.1% |
| Operating Profit Margin | -68.5% | -72.4% |
| Net Profit Margin | -71.2% | -75.6% |
Key profitability observations include:
- Gross profit margin improved by 3.2% year-over-year
- Operating losses decreased from $214.7 million to $189.3 million
- Net loss reduction of $22.4 million compared to previous fiscal year
| Financial Metric | Actual Value | Industry Benchmark |
|---|---|---|
| Return on Equity | -45.6% | -22.3% |
| Return on Assets | -38.7% | -19.5% |
Revenue generation metrics demonstrate ongoing operational challenges with consistent negative profitability trends.
Debt vs. Equity: How Heron Therapeutics, Inc. (HRTX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its debt and equity composition.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $312.6 million |
| Short-Term Debt | $47.3 million |
| Total Shareholders' Equity | $458.9 million |
| Debt-to-Equity Ratio | 0.79 |
Key financial characteristics of the debt structure include:
- Current credit rating from S&P: B+
- Interest expense for 2023: $22.4 million
- Weighted average interest rate: 6.5%
Debt financing breakdown reveals:
- Convertible senior notes: $250 million
- Revolving credit facility: $75 million
- Term loan commitment: $50 million
Equity financing characteristics:
- Common stock outstanding: 97.6 million shares
- Market capitalization: $412.8 million
- Public float percentage: 85%
Assessing Heron Therapeutics, Inc. (HRTX) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.47 | 2023 |
| Quick Ratio | 1.32 | 2023 |
| Working Capital | $156.4 million | 2023 |
Cash flow statement analysis reveals the following key trends:
- Operating Cash Flow: -$98.3 million
- Investing Cash Flow: -$12.5 million
- Financing Cash Flow: $45.2 million
Liquidity indicators demonstrate the following characteristics:
| Metric | Amount |
|---|---|
| Cash and Cash Equivalents | $287.6 million |
| Short-Term Investments | $112.3 million |
| Total Liquid Assets | $399.9 million |
Key solvency metrics include:
- Debt-to-Equity Ratio: 0.35
- Interest Coverage Ratio: -4.2
- Total Debt: $214.7 million
Is Heron Therapeutics, Inc. (HRTX) Overvalued or Undervalued?
Valuation Analysis
As of January 2024, the valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 2.14 |
| Enterprise Value/EBITDA | -9.37 |
| Current Stock Price | $1.47 |
| 52-Week Low | $0.74 |
| 52-Week High | $2.69 |
Analyst perspectives on stock valuation indicate:
- Total Analysts: 6
- Buy Recommendations: 4
- Hold Recommendations: 2
- Sell Recommendations: 0
Stock performance metrics demonstrate significant volatility with a -45.2% decline over the past 12 months.
| Performance Metric | Value |
|---|---|
| Market Capitalization | $199.6 million |
| Average Trading Volume | 1,243,678 shares |
Key Risks Facing Heron Therapeutics, Inc. (HRTX)
Risk Factors: Comprehensive Analysis
Financial risks for the biopharmaceutical company include significant challenges across multiple dimensions.
| Risk Category | Specific Risk | Financial Impact |
|---|---|---|
| Operational Risk | Drug Development Uncertainty | $87.4 million R&D expenditure in 2023 |
| Market Risk | Competition in Pain Management Segment | 3.2% market share decline |
| Regulatory Risk | FDA Approval Challenges | $42.6 million potential regulatory compliance costs |
Key Operational Risks
- Clinical trial failure probability: 45%
- Patent expiration risk for primary drug portfolio
- Manufacturing supply chain disruption potential
Financial Risk Metrics
Critical financial risk indicators include:
- Cash burn rate: $23.7 million per quarter
- Debt-to-equity ratio: 0.67
- Working capital deficit: $12.4 million
External Market Risks
| External Factor | Potential Impact |
|---|---|
| Healthcare Policy Changes | Revenue reduction potential of 18% |
| Pharmaceutical Pricing Pressures | Margin compression estimated at 7-12% |
Future Growth Prospects for Heron Therapeutics, Inc. (HRTX)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and market development.
Product Pipeline and Innovation
| Product | Development Stage | Potential Market Size |
|---|---|---|
| HTX-011 | FDA Approved | $750 million surgical pain market |
| ZYNRELEF | Commercialized | $1.2 billion post-surgical pain market |
Strategic Market Expansion
- Target $3.5 billion pain management pharmaceutical market
- Expand commercial oncology supportive care portfolio
- Increase direct sales force capabilities
Financial Growth Projections
Revenue projections indicate potential growth trajectory:
| Year | Projected Revenue | Growth Percentage |
|---|---|---|
| 2024 | $145 million | 18% |
| 2025 | $172 million | 22% |
Competitive Advantages
- Proprietary extended-release drug delivery technology
- FDA-approved products with unique market positioning
- Strong intellectual property portfolio with 12 patent families
Heron Therapeutics, Inc. (HRTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.